Erectile Dysfunction in Diabetes Mellitus

被引:299
作者
Malavige, Lasantha S. [1 ,2 ,3 ]
Levy, Jonathan C. [1 ,2 ]
机构
[1] Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 7LJ, England
[2] Oxford Radcliffe Trust, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England
[3] Univ Sri Jayewardenepura, Dept Med, Nugegoda, Sri Lanka
关键词
Erectile Dysfunction; Diabetes; Hypogonadism; Testosterone; PDE5; Inhibitors; Pathophysilogy; QUALITY-OF-LIFE; RISK-FACTORS; PEYRONIES-DISEASE; INSULIN-RESISTANCE; ENDOTHELIAL DYSFUNCTION; INTERNATIONAL INDEX; SEXUAL DYSFUNCTION; METABOLIC SYNDROME; CORPORA CAVERNOSA; GLYCEMIC CONTROL;
D O I
10.1111/j.1743-6109.2008.01168.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is reaching pandemic levels and young-onset type 2 diabetes is becoming increasingly common. Erectile dysfunction (ED) is a common and distressing complication of diabetes. The pathophysiology and management of diabetic ED is significantly different to nondiabetic ED. To provide an update on the epidemiology, risk factors, pathophysiology, and management of diabetic ED. Literature for this review was obtained from Medline and Embase searches and from relevant text books. A comprehensive review on epidemiology, risk factors, pathophysiolgy, and management of diabetic ED. Large differences in the reported prevalence of ED from 35% to 90% among diabetic men could be due to differences in methodology and population characteristics. Advancing age, duration of diabetes, poor glycaemic control, hypertension, hyperlipidemia, sedentary lifestyle, smoking, and presence of other diabetic complications have been shown to be associated with diabetic ED in cross-sectional studies. Diabetic ED is multifactorial in aetiology and is more severe and more resistant to treatment compared with nondiabetic ED. Optimized glycaemic control, management of associated comorbidities and lifestyle modifications are essential in all patients. Psychosexual and relationship counseling would be beneficial for men with such coexisting problems. Hypogonadism, commonly found in diabetes, may need identification and treatment. Maximal doses of phosphodiesterase type 5 (PDE5) inhibitors are often needed. Transurethral prostaglandins, intracavenorsal injections, vacuum devices, and penile implants are the available therapeutic options for nonresponders to PDE5 inhibitors and for whom PDE5 inhibitors are contraindicated. Premature ejaculation and reduced libido are conditions commonly associated with diabetic ED and should be identified and treated. Aetiology of diabetic ED is multifactorial although the relative significance of these factors are not clear. A holistic approach is needed in the management of diabetic ED. Malavige LS, and Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-1247.
引用
收藏
页码:1232 / 1247
页数:16
相关论文
共 134 条
  • [1] Prevalence and risk factors for erectile dysfunction in Korean men: Results of an epidemiological study
    Ahn, Tai Young
    Park, Jong Kwan
    Lee, Sung Won
    Hong, Jun Hyuk
    Park, Nam Cheol
    Kim, Je Jong
    Park, Kwangsung
    Park, Hyesook
    Hyun, Jae Seog
    [J]. JOURNAL OF SEXUAL MEDICINE, 2007, 4 (05) : 1269 - 1276
  • [2] Type 2 diabetes in the young: The evolving epidemic - The International Diabetes Federation Consensus Workshop
    Alberti, G
    Zimmet, P
    Shaw, J
    Bloomgarden, Z
    Kaufman, F
    Silink, M
    [J]. DIABETES CARE, 2004, 27 (07) : 1798 - 1811
  • [3] The prevalence of comorbid depression in adults with diabetes - A meta-analysis
    Anderson, RJ
    Freedland, KE
    Clouse, RE
    Lustman, PJ
    [J]. DIABETES CARE, 2001, 24 (06) : 1069 - 1078
  • [4] TESTOSTERONE CONCENTRATIONS IN WOMEN AND MEN WITH NIDDM
    ANDERSSON, B
    VERMEULEN, A
    MARIN, P
    BJORNTORP, P
    LISSNER, L
    [J]. DIABETES CARE, 1994, 17 (05) : 405 - 411
  • [5] Endothelial dysfunction precedes atherosclerotic lesions and platelet activation in high fat diet-induced prothrombotic state
    Aoki, R
    Ikarugi, H
    Naemura, A
    Ijiri, Y
    Yamashita, T
    Yamamoto, J
    [J]. THROMBOSIS RESEARCH, 2006, 117 (05) : 529 - 535
  • [6] The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction
    Arafa, M.
    Eid, H.
    El-Badry, A.
    Ezz-Eldine, K.
    Shamloul, R.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (02) : 213 - 217
  • [7] Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction
    Aversa, A
    Isidori, AM
    Spera, G
    Lenzi, A
    Fabbri, A
    [J]. CLINICAL ENDOCRINOLOGY, 2003, 58 (05) : 632 - 638
  • [8] Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve
    Baba, K
    Yajima, M
    Carrier, S
    Akkus, E
    Reman, J
    Nunes, L
    Lue, TF
    Iwamoto, T
    [J]. UROLOGY, 2000, 56 (03) : 533 - 538
  • [9] Association of type and duration of diabetes with erectile dysfunction in a large cohort of men
    Bacon, CG
    Hu, FB
    Giovannucci, E
    Glasser, DB
    Mittleman, MA
    Rimm, EB
    [J]. DIABETES CARE, 2002, 25 (08) : 1458 - 1463
  • [10] Bancroft J, 1996, DIABETIC MED, V13, P84, DOI 10.1002/(SICI)1096-9136(199601)13:1<84::AID-DIA16>3.0.CO